Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Why Genprex Shares Are Soaring Today
10:43am, Monday, 03'rd Jan 2022
Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combinati
Genprex targets non-small cell lung cancer and diabetes via gene therapy
09:37am, Monday, 03'rd Jan 2022
Focused on developing life-changing therapies for patients with cancer and diabetes Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with
Genprex wins Fast Track designation for REQORSA in combo with Keytruda for treating Non-Small Cell Lung Cancer from FDA
09:33am, Monday, 03'rd Jan 2022
Genprex, Inc. (NASDAQ:GNPX) revealed that the US Food and Drug Administration (FDA) granted Fast Track designation to the company's lead drug candidate, REQORSA Immunogene Therapy, in combination wit
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
09:21am, Monday, 03'rd Jan 2022
The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc
Geode Capital Management LLC Has $1.20 Million Stock Position in Genprex, Inc. (NASDAQ:GNPX)
09:08am, Sunday, 21'st Nov 2021 Dakota Financial News
Geode Capital Management LLC lowered its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 34.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 358,625 shares of the companys stock after selling 188,294 shares during the quarter. Geode Capital Management LLCs []
Genprex: Limited Clinical Data To Justify Risk
01:46pm, Friday, 19'th Nov 2021 Seeking AlphaGenprex: Limited Clinical Data To Justify Risk
08:46am, Friday, 19'th Nov 2021
GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes.
Genprex to Present in November CEO Roadshow Webinar
01:30pm, Tuesday, 16'th Nov 2021 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex''s CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.
5 Top Penny Stocks To Buy For Under $5 On Webull Today
12:39pm, Wednesday, 27'th Oct 2021
Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genprex, Inc. said it has strengthened its leadership team with the appointments of Dr Mark S.
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.
06:50am, Tuesday, 28'th Sep 2021
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with
Genprex to Participate in September Investor Conferences
07:00am, Monday, 20'th Sep 2021
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with
Genprex gears up for patient enrollment in its Acclaim-1 REQORSA trial after FDA feedback
09:30am, Wednesday, 23'rd Jun 2021
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) is gearing up to enroll patients in its Acclaim-1 clinical trial evaluating its lead drug candidate REQORSA in combination with AstraZeneca PLC's (LON:AZN) (NASDAQ:
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer
10:13am, Thursday, 06'th May 2021
Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and re
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung cancer
09:46am, Wednesday, 05'th May 2021
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung c
